DUBLIN – Shares in Gensight Biologics SA gained as much as 25% Monday as the company reported 96-week data from the phase III Rescue trial of its GS-010 gene therapy treatment for patients with Leber hereditary optical neuropathy (LHON) arising from the G11778A mutation in the mitochondrial gene encoding NADH dehydrogenase 4 (ND4). Read More
Shares of Abeona Therapeutics Inc. (NASDAQ:ABEO) fell 12% Monday to $2.87 after the FDA put a clinical hold on a phase III study of its autologous cell therapy for recessive dystrophic epidermolysis bullosa (RDEB), a trial that had initially been slated to start by mid-2019. Read More
Looking closely at the logo for newly launched Omega Therapeutics Inc., there's a definitely an "O" for omega. But there's more. Lurking right there alongside the "O" is also an "A," indicating quite a wide range and vision. Read More
Even when accounting for rebates, Americans pay far more than people in other countries for their prescription drugs, according to a House committee report released Monday. Read More
SUZHOU, China – A recent revision to China's legal infrastructure for the pharma industry represents a concrete step toward bolstering domestic biotech innovation, said stakeholders gathered at last weekend's China Biomed Innovation and Investment Conference. Read More
SUZHOU, China - The global biotech market continues to look promising and Chinese companies are taking notice as they lay the foundation for new advances. Read More
Deinove SA, of Paris, said it expanded its platform with the CRISPR/Cas9 system to enhance its ability to optimize various microorganisms. The objective is to be able to directly manipulate the strains producing antimicrobial activities or to transfer those activities into phylogenetically close frames. Read More
IGM Biosciences Inc., of Mountain View, Calif., said it closed its IPO of approximately 12.6 million common shares, priced at $16 apiece, including the full exercise by underwriters of the overallotment option to purchase approximately 1.6 million additional shares. Read More
Investor-pleasing news from the FDA regarding Dublin-based Avadel Pharmaceuticals plc's pivotal phase III trial testing once-nightly sodium oxybate (FT-218) for narcolepsy sparked Wall Street speculation regarding what the update might mean for Jazz Pharmaceuticals plc, also of Dublin, which markets twice-nightly Xyrem (sodium oxybate) in the space. Read More
